Skip to main content

Sacituzumab Govitecan-hziy

Placeholder slot
 (SAK-ih-TOO-zoo-mab GOH-vih-TEE-kan)

This page contains brief information about sacituzumab govitecan-hziy and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Sacituzumab govitecan-hziy is approved to treat:

¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, confirmatory trial(s) must show that sacituzumab govitecan-hziy provides a clinical benefit in these patients.

Sacituzumab govitecan-hziy is also being studied in the treatment of other types of cancer.

More About Sacituzumab Govitecan-hziy

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Sacituzumab Govitecan-hziy - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Sacituzumab Govitecan Earns Full Approval for Triple-Negative Breast Cancer

Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer

Monoclonal Antibodies

Clinical Trials Accepting Patients

Find Clinical Trials for Sacituzumab Govitecan-hziy - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: